Physician profile
Christopher E Jenkins
NPI 1124373857
$4,390.38
in general payments reported to CMS, 2019-2025
24 companies · $1,070 in 2025
The $1,070 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $574 · 2022: $914 · 2023: $910 · 2024: $923 · 2025: $1,070.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,902.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $925.30 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $599.25 | 2022-2025 | |
| Novo Nordisk INC | $589.16 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $365.36 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $304.07 | 2024-2025 | |
| Esperion Therapeutics, INC. | $286.06 | 2021-2023 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $221.76 | 2021-2024 | Rexulti |
| Amgen INC. | $200.97 | 2021-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $169.34 | 2021-2025 | |
| Surmodics, INC. | $133.85 | 2022 | |
| Exact Sciences Corporation | $122.83 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $64.95 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Pfizer INC. | $61.88 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $61.51 | 2024-2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.41 | 2022-2023 | Jardiance |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $38.68 | 2023 | Arexvy, Shingrix |
| Kowa Pharmaceuticals America, INC. | $32.96 | 2023 | Seglentis, Livalo |
| Phathom Pharmaceuticals, INC. | $32.93 | 2025 | Voquezna |
| Almatica Pharma LLC | $28.81 | 2021 | |
| Janssen Pharmaceuticals, INC | $28.66 | 2022-2023 | Xarelto |
| Astellas Pharma US INC | $28.63 | 2025 | Veozah |
| Tosoh Bioscience, INC. | $22.51 | 2021 | |
| Lundbeck LLC | $16.27 | 2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $12.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Jenkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.